Beijing Tong Ren Tang Chinese Medicine Receives Hong Kong Proprietary Chinese Medicine Registration for Antelope Horn Powder Capsules
Key Highlights for Investors
- Regulatory Milestone Achieved: Beijing Tong Ren Tang Chinese Medicine Company Limited (the Company, stock code: 3613) has obtained the Certificate of Registration of Proprietary Chinese Medicine from the Chinese Medicine Council of Hong Kong for its new product, Antelope Horn Powder Capsules【Tong Ren Tang】 (羚羊角粉膠囊【同仁堂】).
- Market Access: This certification enables the company to sell the Antelope Horn Powder Capsules in the Hong Kong Special Administrative Region, potentially opening new market opportunities.
- Research and Development Investment: The company invested approximately HK\$1,830,000 (unaudited) in R&D for this product.
- Product Details: The capsules are indicated for a wide range of conditions, including pacifying the liver, extinguishing wind, clearing the liver, improving vision, dissipating blood, and removing toxins. Clinically, it is intended for internal stirring of liver wind, epilepsy-related conditions, high fever with convulsions, headache, dizziness, eye conditions, skin infections, and more.
- Certificate Validity: The registration number is HKC-18854, valid until 21 May 2031.
- Product Not Yet Launched: As of the date of the announcement, this product has not yet been introduced to the market.
- Short-term Impact: Management does not expect this certification to have a material impact on the company’s production, operations, or financial performance in the immediate future.
- Potential Risks: The company highlights that sales of pharmaceutical products in Hong Kong can be influenced by policy changes, exchange rate fluctuations, and market competition.
Details and Analysis
The Board of Beijing Tong Ren Tang Chinese Medicine Company Limited announced that it has received regulatory approval from the Chinese Medicine Council of Hong Kong for its Antelope Horn Powder Capsules. This certification is an important step for the company as it broadens its product portfolio and allows entry into the Hong Kong proprietary Chinese medicine market, a lucrative and competitive segment.
The product’s diverse indications may support market adoption, especially given the strong brand recognition of Tong Ren Tang in Chinese medicine. The company has committed significant R&D resources to this development, with a total investment of approximately HK\$1.83 million (unaudited) to date. The product’s certification is valid for five years, providing a stable regulatory window for commercialization efforts.
However, investors should be aware that despite this regulatory milestone, the product has yet to be launched, and management does not anticipate an immediate material effect on the company’s financials. The actual impact will depend on market acceptance, regulatory environment continuity, competitive dynamics, and macroeconomic factors such as currency fluctuations.
Shareholders and potential investors should monitor the commercial launch and early sales performance, as any unexpected success or setbacks could affect share price volatility.
Board Composition (As of Announcement Date)
- Executive Directors: Mr. Yan Han (Chairman), Mr. Yue Zheng (Vice Chairman), Mr. Wang Chi
- Non-executive Director: Ms. Feng Li
- Independent Non-executive Directors: Mr. Tsang Yok Sing, Jasper; Mr. Xu Hong Xi; Mr. Chan Ngai Chi
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own research and consult professional advisors before making any investment decisions. The information above is based on publicly available disclosures and may be subject to change.
北京同仁堂國藥獲香港註冊中成藥證書，羚羊角粉膠囊即將進軍香港市場
投資者重點摘要
- 重大監管里程碑：北京同仁堂國藥有限公司（股份代號：3613）成功獲得香港中醫藥管理委員會頒發的《中成藥註冊證明書》，產品為羚羊角粉膠囊【同仁堂】。
- 市場准入：該證書將允許公司在香港特別行政區銷售羚羊角粉膠囊，為公司打開新市場機會。
- 研發投入：公司已累計投入約港幣183萬元（未經審核）作為該產品的研發費用。
- 產品詳情：該膠囊功能及主治包括平肝息風、清肝明目、散瘀解毒。臨床適用於肝風內動、驚癇、抽搐、孕婦癇證、高熱驚厥、癲癇、狂躁、頭痛、眩暈、紅眼、雲翳、溫毒引起的斑疹、腫痈、瘡瘍及皮膚感染等症。
- 證書有效期：註冊號為HKC-18854，有效期至2031年5月21日。
- 產品尚未上市：截至公告日，該產品尚未正式投放市場。
- 短期影響有限：管理層預計該證書的獲得暫時不會對公司的生產、營運及業績產生重大影響。
- 潛在風險：公司提醒，藥品在港銷售受到政策、匯率波動及市場競爭等多重因素影響。
詳細分析
北京同仁堂國藥有限公司董事會宣布，已取得香港中醫藥管理委員會對羚羊角粉膠囊的註冊批准。這一認證不僅擴大了公司的產品線，還進一步打開香港中成藥市場，有助於品牌在該地區的進一步發展。
該產品適應症廣泛，加上同仁堂品牌在中醫藥領域的強大號召力，有望獲得市場認可。公司對該產品的研發投入顯示其對未來市場的高度重視，證書有效期長達五年，為推廣及銷售提供了充足的時間窗口。
但投資者需注意，產品尚未上市，短期內對公司業績的直接影響有限。未來的市場表現將受產品推廣、市場接受度、監管政策和競爭格局等多重因素影響。
建議股東及潛在投資者密切關注產品上市及初期銷售情況，因為任何超預期的表現或挫折都可能帶來股價波動。
董事會組成（公告日）
- 執行董事：韓悅（主席）、岳正（副主席）、王池
- 非執行董事：馮莉
- 獨立非執行董事：曾鈺成、徐鴻禧、陳毅志
免責聲明
本文僅供參考，並不構成任何投資建議。投資者應自行研究並諮詢專業意見後再作投資決定。以上資訊根據公開資料整理，或有變動，敬請留意。
